|
Qiagen
gc tissue microarrays Gc Tissue Microarrays, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/gc tissue microarrays/product/Qiagen Average 90 stars, based on 1 article reviews
gc tissue microarrays - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Anhui Medical University
human gc tissue microarrays (tma) Human Gc Tissue Microarrays (Tma), supplied by Anhui Medical University, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human gc tissue microarrays (tma)/product/Anhui Medical University Average 90 stars, based on 1 article reviews
human gc tissue microarrays (tma) - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
SuperBioChips
snuh-2004-gc tissue microarray  Snuh 2004 Gc Tissue Microarray, supplied by SuperBioChips, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/snuh-2004-gc tissue microarray/product/SuperBioChips Average 90 stars, based on 1 article reviews
snuh-2004-gc tissue microarray - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Human Protein Atlas
gc tissue microarray (tma) cohort Gc Tissue Microarray (Tma) Cohort, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/gc tissue microarray (tma) cohort/product/Human Protein Atlas Average 90 stars, based on 1 article reviews
gc tissue microarray (tma) cohort - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
U.S Biomax Inc
tissue chip with 50 oscc cancer tissues and 10 cancer adjacent normal tongue tissues from patients with medical records Tissue Chip With 50 Oscc Cancer Tissues And 10 Cancer Adjacent Normal Tongue Tissues From Patients With Medical Records, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/tissue chip with 50 oscc cancer tissues and 10 cancer adjacent normal tongue tissues from patients with medical records/product/U.S Biomax Inc Average 90 stars, based on 1 article reviews
tissue chip with 50 oscc cancer tissues and 10 cancer adjacent normal tongue tissues from patients with medical records - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Annals of surgical oncology
Article Title: The combined expression of metaplasia biomarkers predicts the prognosis of gastric cancer
doi: 10.1245/s10434-011-2125-1
Figure Lengend Snippet: Patients’ demographic data of SNUH-2004-GC for tissue microarrays.
Article Snippet: The staining patterns of MUC13, CDH17, OLFM4, KRT20, LGALS4, MUC5AC and REG4 in the SNUH-2004-GC TMA are shown in . fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 1 caption a7 Protein expression using immunohistochemical staining (100x). membranous type MUC13; MUC13m (1a), cytoplasmic type MUC13; MUC13c (1b), CDH17 (1c), LGALS4 (1d), REG4 (1e), OLFM4 (1f), MUC5AC (1g) and KRT20 (1h). table ft1 table-wrap mode="anchored" t5 caption a7 SNUH-2004-GC n=450 Age (yr) 57.5±12.7 Male to Female ratio 2.7 :1 Location Upper 83 (18.4%) Mid 126 (28.0%) Lower 220 (48.9%) Entire 20 (4.4%) Remnant 1 (0.2%) WHO Papillary 2 (0.4%) Well differentiated 30 (6.7%) Moderately differentiated 155 (34.4%) Poorly differentiated 159 (35.3%) Mucinous 14 (3.1%) Signet Ring cell 82 (18.2%) Undetermined 8 (1.8%) Lauren Intestinal 185 (41.1%) Diffuse 185 (41.1%) Mixed 77 (17.1%) Undetermined 3 (0.7%) Lymphatic invasion 262 (58.2%) Venous invasion 77 (17.1%) Perineural invasion 217 (48.2%) Size (cm) 5.6±3.1 metastatic LN 5.6±8.7 Retrieved LN 31.4±12.9 Radicality R0 403 (89.6%) R1/R2 47 (10.4%) T stage T1 128 (28.4%) T2 71 (15.8%) T3 155 (34.4%) T4 96 (21.3%) N stage N0 192 (42.7%) N1 63 (14.0%) N2 60 (13.3%) N3 135 (30.0%) M stage M0 397 (88.2%) M1 53 (11.8%) TNM stage Stage I 157 (34.9%) Stage II 102 (22.7%) Stage III 138 (30.7%) Stage IV 53 (11.8%) F/U month (mo) 49 (0-64) Open in a separate window SNUH-2004-GC indicates the collection of 450 gastric adenocarcinomas resected at Seoul National University Hospital in 2004 (
Techniques: